Questioner to cancer patients MSC-INHP-QCP1 (Questioner to cancer patients, Study MSC-INHP-8800)

Study identification

• EU PAS number:
  EUPAS8800
• Study ID:
  9541
• Official title and acronym:
  Questioner to cancer patients MSC-INHP-QCP1 (Questioner to cancer patients, Study MSC-INHP-8800)
• DARWIN EU® study:
  No
• Study countries:
  Hungary

  Poland

  Switzerland

  Türkiye

  United Kingdom
• Study description:
  Study MSC-INHP-8800The aim and objective of the Study MSC-INHP 8800 is to measure current (baseline) cancer therapies, practices and treatments from the patient point of view and to measure expectations of individual patients for future cancer therapies more specifically to measure current and future standard care of cancer therapy and measure patient outcome, once the new development "the Biosimilars" for cancer are launched. The Study MSC-INHP-8800 examines and follows up on current and future work ethics, believes and knowledge regarding marketing, distribution, prescription, and use of drugs in a society, with special emphasis on the resulting on patient outcome i.e. medical, social and economic consequences once “the Biosimilars” are launched.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Best Care Consulting

Networks

MSC-INHP

Study timelines

Date when funding contract was signed

Planned:11/03/2015

Study start date

Planned:11/03/2015

Actual:16/04/2015

Date of interim report, if expected

Planned:11/06/2016

Date of final study report

Planned:11/06/2020

Sources of funding

Pharmaceutical company and other private sector 

Other

More details on funding

Best Care Consulting, MSC-INHPs

Regulatory

• Was the study required by a regulatory body?:
  No